News

Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...
Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors despite setbacks for GSK in ...
Biopharma happenings in Asia-Pacific including deals and partnerships, grants, preclinical data and other news in brief: Adagene, Beone Medicines, Biocytogen, Brii, Chugai, Conjugatebio, Gero, ...
Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG on July 14 and set a price target of CHF106.00. The company’s shares closed yesterday at CHF96.06. Elev ...
PolyPid’s proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of ...
CAMBRIDGE, MA, USA & MONTREAL, Canada I July 15, 2025 I Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it has entered ...
Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the most notable here.